

## From 28 April 2026 all newborns in Queensland will be screened for GAMT and Tyrosinemia type I

Queensland Health is committed to supporting newborns and families to have the best possible start to life. As part of this, we are introducing guanidinoacetate methyltransferase deficiency (GAMT) and Tyrosinemia type I to the list of conditions that we test for as part of the Newborn Bloodspot Screening (NBS) program.

Introduction of these conditions aligns to the national program and will be implemented from 28 April 2026. Queensland's NBS program continues to achieve a participation rate over 99%, and the introduction of these conditions is another important milestone that contributes to better health outcomes for Queensland families.

For further information please visit the Queensland Health website at [www.qld.gov.au/health/children/babies/newborn-bloodspot-screening](http://www.qld.gov.au/health/children/babies/newborn-bloodspot-screening)